Investor Domain Parters Vii L P
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Domain Parters Vii L P . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Date Form Target Prev
Shares
Current
Shares
Change
(Percent)
Ownership
(Percent)
Change
(Percent)
2021-06-21 13D/A RSLS / ReShape Lifesciences Inc. 1,000,933 62,500
2021-03-15 13D/A 67424L100 / Obalon Therapeutics Inc 1,000,933 1,000,933
2020-10-23 13D/A 67424L100 / Obalon Therapeutics Inc 1,000,933 1,000,933
2019-08-08 13D/A 67424L100 / Obalon Therapeutics Inc 5,654,178 1,000,933
2019-01-11 13G/A EVFM / Evofem Biosciences, Inc. 515,273
2018-08-31 13D 67424L100 / Obalon Therapeutics Inc 4,005,819 5,654,178
2018-01-29 13D/A ESPR / Esperion Therapeutics, Inc. 1,957,894 1,101,080
2017-12-08 13D/A ESPR / Esperion Therapeutics, Inc. 2,286,977 1,957,894
2017-01-09 13G 67424L100 / Obalon Therapeutics Inc 4,005,819
2017-01-09 13G/A EVOK / Evoke Pharma, Inc. 1,052,328 0
2016-01-19 13G/A EVOK / Evoke Pharma, Inc. 1,052,328
2015-09-25 13D/A CLVS / Clovis Oncology Inc 2,081,745 1,286,857
2015-03-25 13D/A ESPR / Esperion Therapeutics, Inc. 2,286,977
2015-03-10 13D/A CLVS / Clovis Oncology Inc 2,081,745
2015-02-05 13G / Achaogen Inc 1,987,049
2015-02-05 13G EVFM / Evofem Biosciences, Inc. 3,091,643
2014-10-30 13D ESPR / Esperion Therapeutics, Inc. 2,636,977
2014-02-06 13G EVOK / Evoke Pharma, Inc. 1,114,327
2014-02-06 13G ESPR / Esperion Therapeutics, Inc. 2,136,977
2014-02-06 13G TNDM / Tandem Diabetes Care, Inc. 3,541,409
2013-06-06 13D/A CLVS / Clovis Oncology Inc 2,581,745
2012-01-13 13D/A OREX / Orexigen Therapeutics, Inc. 7,580,065